About STAAR Surgical Company - Common Stock (STAA)
Staar Surgical Company is a pioneering developer, manufacturer, and marketer of implantable miniature lenses, primarily used in vision correction procedures. Specializing in advanced ophthalmic technologies, the company focuses on innovative solutions for conditions such as myopia and presbyopia. Staar Surgical aims to enhance patient satisfaction and visual outcomes by providing high-quality, innovative products that are designed to improve the overall eye health and well-being of individuals seeking surgical options for improved eyesight. Through its commitment to research and development, the company continues to advance the field of vision correction and expand its global presence in the ophthalmic medical device market. Read More
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) should vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).
Shares of medical lens company STAAR Surgical (NASDAQ:STAA)
jumped 3.9% in the morning session after the company issued a statement to defend its pending merger process with Alcon against claims from activist investors.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC).
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with respect to the proposed acquisition of the Company by Alcon Inc. (“Alcon”) (NYSE: ALC). In addition, Broadwood released a new presentation explaining why it continues to oppose the proposed transaction, which can be viewed here.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders regarding the closing of STAAR’s go-shop period and the revised offer of Alcon Inc. (SIX/NYSE: ALC) to acquire STAAR for $30.75 per share.
Shares of medical lens company STAAR Surgical (NASDAQ:STAA)
jumped 9.8% in the afternoon session after its merger partner, Alcon, increased its cash buyout offer for the company. Under the amended agreement, Alcon raised its bid from $28.00 to $30.75 per share, boosting the medical technology firm's total value to $1.6 billion. This represented an additional $150 million in equity value for STAAR's stockholders. The new, higher offer came after a "go-shop" period, where STAAR Surgical was permitted to look for competing bids, did not result in any other offers. STAAR's board approved the increased price and recommended that its shareholders vote in favor of the deal.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC).
Shares of medical lens company STAAR Surgical (NASDAQ:STAA)
fell 7.1% in the afternoon session after the company announced the expiration of its 'go-shop' period without receiving any competing acquisition proposals, solidifying its pending merger agreement with Alcon Inc.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) today issued the following open letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the proposed sale of the Company to Alcon Inc. (“Alcon”) (NYSE: ALC) on transaction terms that remain unchanged following the conclusion of the Company’s flawed and belated go-shop process.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffirmed its recommendation that shareholders vote “AGAINST” the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC) on the GREEN Proxy Card.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR’s amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m. Eastern Time on December 6, 2025. No proposals were received prior to the expiration.
Looking back on medical devices & supplies - specialty stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the “Special Meeting”) at STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) to remove three directors from the Company’s Board of Directors (the “Board”). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the current agreement to sell the Company to Alcon Inc. (“Alcon”) (NYSE: ALC), and believes changes to STAAR’s Board are needed to restore investor confidence in the Board’s decision making and the sale process.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) to Alcon Inc. (“Alcon”) (NYSE: ALC).
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the Company has agreed with Alcon Inc. (SIX/NYSE: ALC) to amend their merger agreement to allow proactive solicitation by STAAR of third-party proposals to maximize value for all STAAR stockholders.
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after reviewing STAAR’s third quarter earnings press release and Alcon Inc.’s (SIX/NYSE:ALC) November 4, 2025 investor presentation.
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match.
The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
